. 2026 Feb 26;18(2):118. doi: 10.21037/jtd-2025-aw-2240

Table 2. Results of post-hoc pairwise comparisons for univariate analysis of LOS.

No.	Variable	LOS ≥8 days (n=216), n	LOS <8 days (n=526), n	χ²	P
Medical expense payment method
①	Self-pay	1	2	0.000	0.99
①	Resident medical insurance	114	226	0.000	0.99
②	Self-pay	1	2	0.101	0.75
②	Employee medical insurance	101	298	0.101	0.75
③	Resident medical insurance	114	226	6.007	0.01*
③	Employee medical insurance	101	298	6.007	0.01*
Number of diagnoses at discharge
①	0–4	41	192	14.739	<0.001*
①	5–9	108	230	14.739	<0.001*
②	0–4	41	192	23.459	<0.001*
②	≥10	67	104	23.459	<0.001*
③	5–9	108	230	2.630	0.10
③	≥10	67	104	2.630	0.10
BMI (kg/m²)
①	<18.5	9	7	4.280	0.03*
①	18.5–24.9	131	284	4.280	0.03*
②	<18.5	9	7	7.409	0.006*
②	25.0–29.9	68	202	7.409	0.006*
③	<18.5	9	7	7.422	0.006*
③	≥30.0	8	33	7.422	0.006*
④	18.5–24.9	131	284	3.231	0.07
④	25.0–29.9	68	202	3.231	0.07
⑤	18.5–24.9	131	284	2.559	0.11
⑤	≥30.0	8	33	2.559	0.11
⑥	25.0–29.9	68	202	0.620	0.43
⑥	≥30.0	8	33	0.620	0.43
Reason for visit
①	Physical examination	194	500	4.918	0.02*
①	Pulmonary symptoms	14	16	4.918	0.02*
②	Physical examination	194	500	2.348	0.12
②	Others	8	10	2.348	0.12
③	Pulmonary symptoms	14	16	0.022	0.88
③	Others	8	10	0.022	0.88
Tumor pathology
①	Carcinoma in situ	24	124	3.213	0.07
①	Microinvasive carcinoma	50	158	3.213	0.07
②	Carcinoma in situ	24	124	21.458	<0.001*
②	Invasive carcinoma	114	189	21.458	<0.001*
③	Carcinoma in situ	24	124	9.356	0.002*
③	Others	28	55	9.356	0.002*
④	Microinvasive carcinoma	50	158	10.445	0.001*
④	Invasive carcinoma	114	189	10.445	0.001*
⑤	Microinvasive carcinoma	50	158	2.843	0.09
⑤	Others	28	55	2.843	0.09
⑥	Invasive carcinoma	114	189	0.424	0.51
⑥	Others	28	55	0.424	0.51
T component of the TNM staging
①	T0	18	44	4.246	0.03*
①	Tis	25	126	4.246	0.03*
②	T0	18	44	0.132	0.71
②	T1	154	338	0.132	0.71
③	T0	18	44	4.932	0.02*
③	T2 and above	19	18	4.932	0.02*
④	Tis	25	126	12.504	<0.001*
④	T1	154	338	12.504	<0.001*
⑤	Tis	25	126	20.070	<0.001*
⑤	T2 and above	19	18	20.070	<0.001*
⑥	T1	154	338	6.286	0.01*
⑥	T2 and above	19	18	6.286	0.01*
N component of the TNM staging
①	N0	201	513	4.534	0.03*
①	N1	10	10	4.534	0.03*
②	N0	201	513	4.578	0.03*
②	N2	5	3	4.578	0.03*
③	N1	10	10	0.359	0.54
③	N2	5	3	0.359	0.54
Surgical methods
①	Lobectomy	51	54	21.407	<0.001*
①	Wedge resection	111	324	21.407	<0.001*
②	Lobectomy	51	54	16.770	<0.001*
②	Segmentectomy	32	105	16.770	<0.001*
③	Lobectomy	51	54	3.539	0.06
③	Combined resection	14	30	3.539	0.06
④	Lobectomy	51	54	0.771	0.38
④	Others	8	13	0.771	0.38
⑤	Wedge resection	111	324	0.259	0.61
⑤	Segmentectomy	32	105	0.259	0.61
⑥	Wedge resection	111	324	0.823	0.36
⑥	Combined resection	14	30	0.823	0.36
⑦	Wedge resection	111	324	1.643	0.20
⑦	Others	8	13	1.643	0.20
⑧	Segmentectomy	32	105	1.258	0.26
⑧	Combined resection	14	30	1.258	0.26
⑨	Segmentectomy	32	105	2.092	0.14
⑨	Others	8	13	2.092	0.14
⑩	Combined resection	14	30	0.250	0.61
⑩	Others	8	13	0.250	0.61
Chest tube drainage volume (mL)
①	≤200	106	431	31.538	<0.001*
①	201–400	58	77	31.538	<0.001*
②	≤200	106	431	95.695	<0.001*
②	>400	52	18	95.695	<0.001*
③	201–400	58	77	18.188	<0.001*
③	>400	52	18	18.188	<0.001*
Chest tube indwelling time (h)
①	0–24	16	131	11.653	<0.001*
①	25–48	113	358	11.653	<0.001*
②	0–24	16	131	100.307	<0.001*
②	>48	87	37	100.307	<0.001*
③	25–48	113	358	93.767	<0.001*
③	>48	87	37	93.767	<0.001*
ASA physical status score
①	1	0	3	1.137	0.28
①	2	189	498	1.137	0.28
②	1	0	3	2.948	0.08
②	3	25	24	2.948	0.08
③	1	0	3	3.000	0.08
③	4	2	1	3.000	0.08
④	2	189	498	12.258	<0.001*
④	3	25	24	12.258	<0.001*
⑤	2	189	498	2.288	0.13
⑤	4	2	1	2.288	0.13
⑥	3	25	24	0.277	0.59
⑥	4	2	1	0.277	0.59

*, statistical significance (P<0.05). ASA, American Society of Anesthesiologists; BMI, body mass index; LOS, length of stay; TNM, tumor node metastasis.